Evonile Pharma Limited NOVARTIND NSEPHARMA
Company Overview
Evonile Pharma Limited is involved in the pharmaceutical business in India and internationally. It operates Pharma International (Commercial operations), Development (Drug development), Biomedical Research, and Operations. The company offers therapeutic products in the areas of bone and pain under the Voveran brand; transplantation immunology under the Simulect, Certican, Sandimmun, Neoral, and Myfortic brands. It also offers neuroscience products under the Tegrital and Exelon brands. The company was incorporated in 1947 and is based in Mumbai, India. As of July 29, 2026, Evonile Pharma Limited operates as a subsidiary of Waverise Investments Limited.
Why Investors Should Care
Return on capital employed stands at 15.7%.
Maintains a net profit margin of 26.4%.
Carries low leverage with a debt-to-equity ratio of 0.39.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Mar 2026 Revenue of ₹354.33 Cr (-0.5% YoY); net profit ₹93.18 Cr.
- Trailing 12 Months Year-on-year growth — revenue +18.6%, earnings +16.6%.
- 5-Year Trend Long-term compounding — revenue CAGR -1.4%, profit CAGR -3.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -1.35% |
| 1 Year: | 18.60% |
Compounded Profit Growth
| 5 Years: | -3.40% |
| 1 Year: | 16.60% |
Stock Price Performance
| 1 Year: | +163.00% |
| 6 Months: | +83.78% |
| 3 Months: | +5.68% |
| 1 Month: | -11.78% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- RSI (14)37.29 · Neutral
P/E of 43.30 is above the sector median of 36.43 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Excellent profit margin of 26.4%.
- Generates positive free cash flow.
CONS
- Revenue declined at -1.4% CAGR over 5 years.
- Earnings shrank at -3.4% CAGR over 5 years.
- Trading 27.2% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NOVARTIND Evonile Pharma Limited NSEPHARMA | 1,768.00 | 43.30 | ₹4,365.33 Cr | 0.00% | 15.71% | 11.39% | -1.35% | -3.40% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,745.10 | 34.62 | ₹4.19 L Cr | 0.91% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 9,190.00 | 83.58 | ₹2.44 L Cr | 0.32% | 18.96% | 15.32% | 10.98% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,553.80 | 72.74 | ₹1.73 L Cr | 0.81% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,117.30 | 24.90 | ₹1.11 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 6 | LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA | 631.35 | 164.41 | ₹1.09 L Cr | 0.00% | 7.21% | 5.65% | 35.38% | 66.99% |
| 7 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 7,600.00 | 52.32 | ₹1.09 L Cr | 0.25% | 19.20% | 20.48% | 14.85% | 33.34% |
| 8 | LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA | 2,012.50 | 99.48 | ₹1.09 L Cr | 0.12% | 19.53% | 16.77% | 3.77% | 4.00% |
| 9 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,314.00 | 31.51 | ₹1.06 L Cr | 0.99% | 14.86% | 11.27% | 7.23% | 11.45% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | 93.00 Cr | 83.88 Cr | 87.55 Cr | - | 85.90 Cr | 90.55 Cr | 103.81 Cr |
| Cost of Revenue | 50.46 Cr | 49.30 Cr | 46.77 Cr | - | 48.90 Cr | 52.18 Cr | 55.67 Cr |
| Gross Profit | 42.54 Cr | 34.58 Cr | 40.78 Cr | - | 37.00 Cr | 38.37 Cr | 48.14 Cr |
| Operating Expenses | 17.45 Cr | 11.40 Cr | 14.10 Cr | - | 15.15 Cr | 18.24 Cr | 13.62 Cr |
| Operating Income | 25.09 Cr | 23.18 Cr | 26.68 Cr | - | 21.85 Cr | 20.13 Cr | 34.52 Cr |
| EBITDA | 36.18 Cr | 34.54 Cr | 37.85 Cr | - | 31.11 Cr | 30.63 Cr | 43.65 Cr |
| Interest Expense | 36.00 L | 12.00 L | 10.00 L | - | 98.00 L | 7.00 L | 6.00 L |
| Pretax Income | 35.29 Cr | 33.89 Cr | 37.22 Cr | - | 29.65 Cr | 30.14 Cr | 43.17 Cr |
| Tax Provision | 9.84 Cr | 4.59 Cr | 9.60 Cr | - | 13.56 Cr | 4.89 Cr | 10.96 Cr |
| Net Income | 25.45 Cr | 29.30 Cr | 27.62 Cr | - | 16.09 Cr | 25.25 Cr | 32.21 Cr |
| Diluted EPS | - | - | 11.19 | 9.81 | 6.52 | 10.23 | 13.05 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 369.11 Cr | 334.04 Cr | 356.27 Cr | 354.33 Cr |
| Cost of Revenue | - | 204.62 Cr | 202.38 Cr | 202.82 Cr | 198.37 Cr |
| Gross Profit | - | 164.49 Cr | 131.66 Cr | 153.45 Cr | 155.96 Cr |
| Operating Expenses | - | 95.23 Cr | 66.40 Cr | 58.99 Cr | 63.94 Cr |
| Operating Income | - | 69.26 Cr | 65.26 Cr | 94.46 Cr | 92.02 Cr |
| EBITDA | - | 123.19 Cr | 126.94 Cr | 133.38 Cr | 132.87 Cr |
| Interest Expense | - | 1.75 Cr | 1.49 Cr | 77.00 L | 1.26 Cr |
| Pretax Income | - | 115.38 Cr | 122.84 Cr | 130.42 Cr | 129.66 Cr |
| Tax Provision | - | 12.02 Cr | 37.65 Cr | 29.52 Cr | 36.48 Cr |
| Net Income | - | 103.36 Cr | 85.19 Cr | 100.90 Cr | 93.18 Cr |
| Diluted EPS | - | - | 34.50 | 40.87 | 37.74 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 982.94 Cr | 924.93 Cr | 947.81 Cr | 978.27 Cr |
| Current Assets | - | 677.33 Cr | 699.26 Cr | 745.82 Cr | 768.25 Cr |
| Cash & Equivalents | - | 19.42 Cr | 44.98 Cr | 52.07 Cr | 52.50 Cr |
| Inventory | - | 54.72 Cr | 44.86 Cr | 41.11 Cr | 53.32 Cr |
| Receivables | - | 36.16 Cr | 41.47 Cr | 40.14 Cr | 37.05 Cr |
| Total Liabilities | - | 207.28 Cr | 180.11 Cr | 162.85 Cr | 160.44 Cr |
| Current Liabilities | - | 159.49 Cr | 157.20 Cr | 142.05 Cr | 144.97 Cr |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 21.51 Cr | 6.97 Cr | 5.06 Cr | 3.21 Cr |
| Total Equity | - | 775.66 Cr | 744.82 Cr | 784.96 Cr | 817.83 Cr |
| Shares Outstanding | - | 2.47 Cr | 2.47 Cr | 2.47 Cr | 2.47 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 44.80 Cr | 113.40 Cr | 74.57 Cr | 46.73 Cr |
| Investing Cash Flow | - | -153.25 Cr | 33.13 Cr | -3.31 Cr | 17.63 Cr |
| Financing Cash Flow | - | -30.48 Cr | -120.99 Cr | -64.15 Cr | -63.93 Cr |
| Capital Expenditure | -50.00 L | -31.00 L | - | - | -34.00 L |
| Free Cash Flow | - | 44.49 Cr | 113.40 Cr | 74.57 Cr | 46.39 Cr |
| Net Change in Cash | - | -138.93 Cr | 25.54 Cr | 7.11 Cr | 43.00 L |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 44.6% | 39.4% | 43.1% | 44.0% |
| Operating Margin % | - | 18.8% | 19.5% | 26.5% | 26.0% |
| Net Margin % | - | 28.0% | 25.5% | 28.3% | 26.3% |
| ROE % | - | 13.3% | 11.4% | 12.9% | 11.4% |
| ROCE % | - | 8.4% | 8.5% | 11.7% | 11.0% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NOVARTIND
Novartis India Limited Actuals & Estimates (NSE:NOVARTIND) - TradingView
<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxQRXV6OVpkMnl6LWIwNldKZXVFSG5zY0J0VEFXRFRweGJibFlpWWpNV0lDYXJ4ckE2MWVnTzREdVRmb3dDZEJpWW5kZnJqNDZJRGR4ZmI2ZFNtQTRKWTdNM3h4cVk1d3VucnBlOXJrWHBQc25yTTk5UWhieVk2MGxGUnVWTmhLeGNX?oc=5"…
Evonile Pharma Limited: Dividend historical data and projections - marketscreener.com
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxNT2Vka1VrdXRyeWNITHhKSjJkaDlJSm9kVjRNY0JUSW80SFdJc2IwUkpxa2dSNjNyUklYYjRlZDFBbnNkc3k2enVfRGNVV2EwNUYzSDRKdDBpc01GSGhTOFUyaEhTeDIydGd4M2Y3dHNMc2FneFJjWUxFQ3YzTjIxb3JYR09HMnl0dUJjdV…
Evonile Pharma Limited (NOVARTIND.NS) stock price, news, quote and history - Yahoo Finance - Yahoo Finance Singapore
<a href="https://news.google.com/rss/articles/CBMibEFVX3lxTE51RjRDbjhhUEJyQzJWMnNxOTVDTXRKQVl3QW53QjJBdDBYNXBxNmllVDlMbnZYcVV0NFNVUTFhT3U5cDhLNHlvTXdhQWlobmhfMi1LVUpHUG1Fd3Q5YzdDaHotdW5OcUNna2FRTg?oc=5" target="_blank">Evonile Pharma Limite…
Evonile Pharma (NSEI:NOVARTIND) - Stock Analysis - Simply Wall Street
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxQSWstMFgweGhFRmVudTRPUzQ2d3RGT2Vsa0dLNHlzbjN3dzFfbTFDV3d6eWVUM01zSnVleTJ4SEdkcHRGMU9HUlpNNi1DQjZiX09tYmY5Zmx1TFk2ZHpzdks5U2k3SWNCXzk3VWZBSWFWTnFBaVhBWEZRT28wODE5VXhWaE00MUYzYTV3ZU…
Novartis India share price jumps 10% | What lies ahead for the stock? - TradingView
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxNNEFaaGZ4bUFRdjduc2VBVklGUlFRR1BCWUNmOW1sM0xZLWlaR3k4Y1dtejdOZmJDR2xzZDcyc1d1VXZWWV9RWVVPQlhMclRQS0VUX3hSd2RsbUU1bnl6WXV1OWFnSnhCdjdwaGFRWW16ZENheUlkckxRSE9pQkdnN0JPd1R5V3RCOU9ZTU…
Is Novartis (NOVARTIND.NS)'s -1.62% Correction Healthy or a Warning? 2026-10-12 - ETF Liquidity - https://www.siam.in/
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxOenN6bl9kNzNIMU13ZkJ5cUpCV0xvQThJN0NtZmVXN2dQN09RbmdreXBLX1EwVU1yNEVqeTFpLUxYTnl0ZVE1cmY4blkyTHdFdEdoV0VHZWlpTFBycFdvM1BQaXBPT0V0T0U0d2kzbTJCTGpfc2NqV1hKeU51RFJmaFU3QnduQnZHM2RFen…
NOVARTIND — Frequently Asked Questions
What is the current share price of Evonile Pharma Limited (NOVARTIND)?
As of 2026-10-23 04:58 IST, Evonile Pharma Limited (NOVARTIND) trades at ₹1,768.00 on NSE. Its 52-week range is ₹672.25 to ₹2,428.20.
What is the market capitalisation of NOVARTIND?
Evonile Pharma Limited (NOVARTIND) has a market capitalisation of ₹4,365.33 Cr on NSE.
What is the P/E ratio of NOVARTIND?
NOVARTIND trades at a trailing price-to-earnings (P/E) ratio of 43.30. The industry average P/E is 36.43. Its price-to-book (P/B) ratio is 6.18.
What is the return on equity (ROE) of NOVARTIND?
NOVARTIND has a return on equity (ROE) of 11.39%. Its return on capital employed (ROCE) is 15.71%.
Is NOVARTIND a good stock to buy?
This page provides a data-driven analysis of Evonile Pharma Limited (NOVARTIND), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.